Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672164 · ClinicalTrials.gov registry record
Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 202
- Enrollment target
NCT01672164: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01672164 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 202 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01672164 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 202 participants
- Enrollment target
Study Summary
The main focus of this study is to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had a liver transplant. Researchers will examine blood, urine, and tissue samples and try to identify markers for certain conditions such as rejection, response to therapy, and scarring of the liver. Additionally, researchers would like to identify biomarkers that can detect damage to the native kidneys before blood levels of creatinine rises. By studying gene expression, researchers hope to be able to diagnose these conditions earlier and improve liver survival.
Primary Outcome
The primary endpoint is the incidence of biopsy proven AR at 3, 12 and 24 months after LT.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-12 |
What the finished NCT01672164 record still lists
NCT01672164 is an observational study that tracks outcomes without assigning an intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01672164 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01672164 about?
NCT01672164 is a clinical study titled "Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients". The main focus of this study is to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had a liver transplant. Researchers will examine blood, urine, and tissue samples and try to identify markers for certain conditions such as rejection, response to...
What is the current status of trial NCT01672164?
This trial is currently completed. The enrollment target is 202 participants. The study started on 2012-08. Estimated completion is 2015-12.
Who is sponsoring clinical trial NCT01672164?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia